VivoSim Labs, INC. (VIVS) shareholders
Close on Nov 17, 2026Market cap $383.64KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Esousa Group Holdings LLC Joint filing with Michael Wachs (9.90%) | 319,429 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VIVS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 25,976 | 0.17% | $27.80K | −10,874 | 0.00% |
| Renaissance Technologies LLC | 18,500 | 0.12% | $19.80K | New | 0.00% |
| Hrt Financial LP | 18,319 | 0.12% | $19.00K | New | 0.00% |
| Vanguard Capital Management LLC | 15,371 | 0.10% | $16.45K | – | 0.00% |
| BlackRock, Inc. | 11,817 | 0.08% | $12.64K | – | 0.00% |
| Vanguard Fiduciary Trust Co | 7,003 | 0.05% | $7.49K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 5,249 | 0.04% | $5.62K | +2,941 | 0.00% |
| SBI Securities Co., Ltd. | 221 | 0.00% | $236 | – | 0.00% |
| FNY Investment Advisers, LLC | 200 | 0.00% | $0 | New | 0.00% |
| Larson Financial Group LLC | 166 | 0.00% | $178 | – | 0.00% |
| Albion Financial Group /Ut | 159 | 0.00% | $171 | – | 0.00% |
| Wells Fargo & Company/Mn | 111 | 0.00% | $119 | – | 0.00% |
| Osaic Holdings, Inc. | 84 | 0.00% | $88 | −11 | 0.00% |
| Morgan Stanley | 49 | 0.00% | $52 | −1 | 0.00% |
| UBS Group AG | 18 | 0.00% | $20 | −934 | 0.00% |
| Caitong International Asset Management Co., Ltd | 17 | 0.00% | $18 | +14 | 0.00% |
| IFG Advisory, LLC | 14 | 0.00% | $15 | New | 0.00% |
| Integrated Wealth Concepts LLC | 8 | 0.00% | $9 | New | 0.00% |
| Activest Wealth Management | 2 | 0.00% | $2 | – | 0.00% |
| Golden State Wealth Management, LLC | 2 | 0.00% | $2 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 26 | 0M | 0.7% | 5 / 2 | 5 / 3 | 0M | 0M |
| Q1 2026 | 24 | 0M | 0.7% | 5 / 4 | 2 / 7 | 0M | 0M |
| Q4 2025 | 27 | 0M | 0.7% | 5 / 3 | 6 / 7 | 0M | 0M |
| Q3 2025 | 29 | 0M | 1.5% | 11 / 7 | 4 / 8 | 0M | 0M |
| Q2 2025 | 26 | 0M | 0.9% | 8 / 5 | 3 / 5 | 0M | 0M |
| Q1 2025 | 23 | 0M | 0.4% | 23 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held VIVS in Q2 2026, 34% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of VIVS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 24,544 | 0.17% | $32.15K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 15,371 | 0.10% | $16.45K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 4,055 | 0.03% | $5.31K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 991 | 0.01% | $1.30K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Keith Murphy | EXECUTIVE CHAIRMAN, Director | 6,094,968 | 41.04% | Jan 29, 2026 |
| Tony Serge Lialin | Chief Commercial Officer | 10,000 | 0.07% | Sep 1, 2026 |
| Amar Akhtar Sethi | Chief Scientific Officer | – | – | Nov 26, 2025 |
| Norm Staskey | See Remarks | – | – | Jan 8, 2025 |
| David Gobel | Director | 15,000 | 0.10% | Jan 29, 2026 |
| Douglas Jay Cohen | Director | 20,898 | 0.14% | Jan 29, 2026 |
| Adam K. Stern | Director | 522,988 | 3.52% | Jan 29, 2026 |
| Alison Tjosvold Milhous | Director | 19,899 | 0.13% | Jan 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Tony Serge Lialin Chief Commercial Officer | Aug 31, 2026 | Buy | +10,000 | $0.28 | $2.80K | 10,000 |
| Keith Murphy EXECUTIVE CHAIRMAN, Director | Jan 27, 2026 | Award | +15,000 | – | – | 26,053 |
| Alison Tjosvold Milhous Director | Jan 27, 2026 | Award | +15,000 | – | – | 19,899 |
| Adam K. Stern Director | Jan 27, 2026 | Award | +15,000 | – | – | 19,899 |
| David Gobel Director | Jan 27, 2026 | Award | +15,000 | – | – | 15,000 |
| Douglas Jay Cohen Director | Jan 27, 2026 | Award | +15,000 | – | – | 20,732 |
| David Gobel Director | Nov 17, 2025 | Sale | +3,266 | $2.24 | $7.32K | 0 |
| David Gobel Director | Aug 7, 2024 | Award | +19,607 | – | – | 39,214 |
| Douglas Jay Cohen Director | Aug 7, 2024 | Award | +19,607 | – | – | 68,821 |
| Alison Tjosvold Milhous Director | Aug 7, 2024 | Award | +19,607 | – | – | 58,821 |
| Adam K. Stern Director | Aug 7, 2024 | Award | +19,607 | – | – | 58,821 |
| Vaidehi Joshi Director | Aug 7, 2024 | Award | +19,607 | – | – | 58,821 |
| Keith Murphy EXECUTIVE CHAIRMAN, Director | Aug 7, 2024 | Award | +19,607 | – | – | 132,641 |
| Alison Tjosvold Milhous Director | Nov 17, 2023 | Award | +19,607 | – | – | 39,214 |
| Keith Murphy Executive Chairman, Director | Nov 17, 2023 | Award | +19,607 | – | – | 113,034 |
| Douglas Jay Cohen Director | Nov 17, 2023 | Award | +19,607 | – | – | 49,214 |
| David Gobel Director | Nov 17, 2023 | Award | +19,607 | – | – | 19,607 |
| Vaidehi Joshi Director | Nov 17, 2023 | Award | +19,607 | – | – | 39,214 |
| Adam K. Stern Director | Nov 17, 2023 | Award | +19,607 | – | – | 39,214 |
| David Gobel Director | Nov 15, 2023 | Sale | −19,607 | $1.62 | $31.76K | 0 |
| Alison Tjosvold Milhous Director | Nov 10, 2022 | Award | +19,607 | – | – | 19,607 |
| Douglas Jay Cohen Director | Nov 10, 2022 | Award | +19,607 | – | – | 29,607 |
| Adam K. Stern Director | Nov 10, 2022 | Award | +19,607 | – | – | 19,607 |
| Keith Murphy Executive Chairman, Director | Nov 10, 2022 | Award | +19,607 | – | – | 93,427 |
| Vaidehi Joshi Director | Nov 10, 2022 | Award | +19,607 | – | – | 19,607 |
| David Gobel Director | Nov 10, 2022 | Award | +19,607 | – | – | 19,607 |
| David Gobel Director | Nov 19, 2021 | Sale | −145 | $5.29 | $767 | 0 |
| Douglas Jay Cohen Director | Aug 17, 2021 | Buy | +1,000 | $6.72 | $6.72K | 1,000 |
| Douglas Jay Cohen Director | Aug 17, 2021 | Buy | +1,000 | $6.74 | $6.74K | 1,000 |
| Douglas Jay Cohen Director | Aug 17, 2021 | Buy | +8,750 | $6.72 | $58.80K | 10,000 |
| Keith Murphy Executive Chairman, Director | Mar 8, 2021 | Award | +20,000 | – | – | 66,320 |
| Jennifer Bush General Counsel & Secretary | Aug 18, 2020 | Tax withholding | −10,900 | $0.57 | $6.21K | 192,758 |
| Craig Kussman Chief Financial Officer | Aug 18, 2020 | Tax withholding | −15,700 | $0.57 | $8.95K | 221,743 |
| Taylor Crouch CEO & President, Director | Aug 18, 2020 | Tax withholding | −5,510 | $0.57 | $3.14K | 125,144 |
| Jennifer Bush General Counsel & Secretary | May 18, 2020 | Tax withholding | −14,630 | $0.51 | $7.46K | 203,658 |
| Taylor Crouch CEO & President, Director | May 18, 2020 | Tax withholding | −6,340 | $0.51 | $3.23K | 130,654 |
| Craig Kussman Chief Financial Officer | May 18, 2020 | Tax withholding | −18,030 | $0.51 | $9.20K | 237,443 |
| Craig Kussman Chief Financial Officer | Feb 19, 2020 | Tax withholding | −17,100 | $0.32 | $5.47K | 255,473 |
| Taylor Crouch CEO & President, Director | Feb 19, 2020 | Tax withholding | −6,045 | $0.32 | $1.93K | 136,994 |
| Jennifer Bush General Counsel & Secretary | Feb 19, 2020 | Tax withholding | −13,850 | $0.32 | $4.43K | 218,288 |
| Jennifer Bush General Counsel & Secretary | Nov 18, 2019 | Tax withholding | −11,695 | $0.45 | $5.26K | 232,138 |
| Craig Kussman Chief Financial Officer | Nov 18, 2019 | Tax withholding | −14,410 | $0.45 | $6.48K | 272,573 |
| Taylor Crouch CEO & President, Director | Nov 18, 2019 | Tax withholding | −5,075 | $0.45 | $2.28K | 143,039 |
| Paul Gallant General Manager | Aug 16, 2019 | Tax withholding | −9,500 | $0.29 | $2.76K | 191,335 |
| Craig Kussman Chief Financial Officer | Aug 16, 2019 | Tax withholding | −14,750 | $0.29 | $4.28K | 286,983 |
| Steven George Hughes Chief Medical Officer | Aug 16, 2019 | Sale | −22,230 | $0.29 | $6.45K | 138,484 |
| Jennifer Bush General Counsel & Secretary | Aug 16, 2019 | Tax withholding | −11,960 | $0.29 | $3.47K | 243,833 |
| Taylor Crouch CEO & President, Director | Aug 16, 2019 | Tax withholding | −5,300 | $0.29 | $1.54K | 148,114 |
| Craig Kussman Chief Financial Officer | May 16, 2019 | Tax withholding | −15,155 | $0.97 | $14.70K | 301,733 |
| Jennifer Bush General Counsel & Secretary | May 16, 2019 | Tax withholding | −12,275 | $0.97 | $11.91K | 255,793 |
| Paul Gallant General Manager | May 16, 2019 | Tax withholding | −9,274 | $0.97 | $9.00K | 200,835 |
| Taylor Crouch CEO & President, Director | May 16, 2019 | Tax withholding | −5,465 | $0.97 | $5.30K | 153,414 |
| Paul Gallant General Manager | Feb 19, 2019 | Tax withholding | −10,410 | $1.07 | $11.14K | 210,109 |
| Jennifer Bush General Counsel & Secretary | Feb 19, 2019 | Tax withholding | −13,520 | $1.07 | $14.47K | 268,068 |
| Taylor Crouch CEO & President, Director | Feb 19, 2019 | Tax withholding | −5,665 | $1.07 | $6.06K | 158,879 |
| Craig Kussman Chief Financial Officer | Feb 19, 2019 | Tax withholding | −16,215 | $1.07 | $17.35K | 316,888 |
| Paul Gallant General Manager | Nov 16, 2018 | Tax withholding | −9,450 | $1.07 | $10.11K | 220,519 |
| Jennifer Bush General Counsel & Secretary | Nov 16, 2018 | Tax withholding | −11,915 | $1.07 | $12.75K | 281,588 |
| Taylor Crouch CEO & President, Director | Nov 16, 2018 | Tax withholding | −5,140 | $1.07 | $5.50K | 164,544 |
| Craig Kussman Chief Financial Officer | Nov 16, 2018 | Tax withholding | −14,720 | $1.07 | $15.75K | 333,103 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of VivoSim Labs's stock actually held short. Settlement fails (shares not delivered on time) peaked at 47,140 shares on Sep 17, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David Gobel Director | Nov 15, 2023 | 19,607 | $31.75K | Nov 15, 2023 | RSU GRAN VEST |
Congress trades
1 trade in VivoSim Labs reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| William L. Owens NY21 | Bought | Nov 6, 2014 | $1K–15K | Nov 13, 2014 |
See a number that looks wrong?